Consideration of confounders, accuracy of diagnosis, and disease severity in assessing the risk of inflammatory bowel disease in patients with psoriasis and psoriatic arthritis/ankylosing spondylitis beginning interleukin‐7 inhibitor treatment: comment on the article by Penso et al